Repurposed alcoholism drug fights liver cancer by targeting fat metabolism and blood supply
- Details
- Category: Research
Hepatocellular carcinoma (HCC) is a leading cause of cancer death worldwide, often driven by abnormal lipid metabolism and excessive blood vessel growth. In a new study, researchers from Fudan University and Wenzhou Medical University have uncovered how disulfiram - a long-used anti-alcoholism medication - exerts potent anti-tumor effects in liver cancer.
Integrating heart imaging and proteomics identifies drug targets for cardiovascular diseases
- Details
- Category: Research
Cardiovascular diseases (CVDs) remain a leading cause of global morbidity and mortality, with significant residual risk unexplained by traditional factors. The discovery of novel therapeutic targets or the repurposing of existing drug targets could improve the prevention and treatment for different CVDs. However, previous studies have encountered different analytic challenges, such as failing to cover the whole spectrum of CVDs,
Multiple myeloma: Established cancer drug reactivates immunotherapy
- Details
- Category: Research
Genetically modified immune cells can offer precious additional time to patients with advanced multiple myeloma. However, these therapies lose their impact as the molecules on cancer cells that immune cells recognize gradually vanish. Researchers at the Technical University of Munich (TUM) have now identified one of the molecular mechanisms behind this process. In an initial study they succeeded in blocking it using an existing cancer drug.
Why people won't quit a weight loss drug - even when it makes them feel sick
- Details
- Category: Research
Patients who use semaglutide for weight loss, like Ozempic, are more likely to continue the medication if they perceive it as effective, even when facing unpleasant side effects, according to Rutgers Health researchers.
Their study, published in Journal of Medical Internet Research, found perceived effectiveness - reductions in weight, appetite or food cravings - was the strongest predictor of satisfaction and intention to continue treatment, regardless of side effects.
AI that understands chemical principles... Accelerating the development of new drugs and materials
- Details
- Category: Research
Whether a smartphone battery lasts longer or a new drug can be developed to treat incurable diseases depends on how stably the atoms constituting the material are bonded. The core of 'molecular design' lies in finding how to arrange these countless atoms to form the most stable molecule. Until now, this process has been as difficult as finding the lowest valley in a massive mountain range, requiring immense time and costs.
Statins do not cause the majority of side effects listed in package leaflets
- Details
- Category: Research
Cardiovascular disease results in around 20 million deaths worldwide and causes around a quarter of all deaths in the UK. Statins are highly effective drugs that lower LDL ("bad") cholesterol levels and have been repeatedly proven to reduce the risk of cardiovascular disease. However, there have been concerns about possible side effects.
Innovative ‘poop pills’ show promising results in clinical trials for multiple types of cancer
- Details
- Category: Research
Fecal microbiota transplants (FMT), can dramatically improve cancer treatment, suggest two groundbreaking studies published in the prestigious Nature Medicine journal. The first study shows that the toxic side effects of drugs to treat kidney cancer could be eliminated with FMT. The second study suggests FMT is effective in improving the response to immunotherapy in patients with lung cancer and melanoma.
More Pharma News ...
- How a heart medication could unlock a new targeted approach in lymphoma
- A broken DNA repair tool accelerates aging
- Metformin shown to prevent Long COVID across risk groups in multiple randomized trials
- Two days of oatmeal reduce cholesterol level
- Chemotherapy rewires gut bacteria to curb metastasis
- New nanoparticle technology offers hope for hard-to-treat diseases
- Oxford team engineer quantum-enabled proteins, opening a new frontier in biotechnology